Core Viewpoint - Baoji Pharmaceutical (02659) has successfully listed its shares at a price of HKD 26.38 per share, raising approximately HKD 922 million, with a significant initial trading surge of 129.34% to HKD 60.5 per share, indicating strong market interest and investor confidence in the company's potential [1][1][1] Company Overview - Baoji Pharmaceutical is a biotechnology company in the clinical and commercialization stages, focusing on developing and providing recombinant biopharmaceuticals in China using synthetic biology technology [1][1] - The company targets high-value therapeutic markets with complex drug manufacturing processes, including large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproductive drugs, and transformative products that replace traditional biochemical products [1][1] Key Products - The company has developed China's first recombinant hyaluronidase, KJ017, for large-volume subcutaneous delivery [1][1] - KJ103, a global first with "best-in-class" potential in low pre-storage antibodies and dosing frequency, is aimed at treating antibody-mediated autoimmune diseases [1][1] - SJ02, a long-acting follicle-stimulating hormone drug, has been validated through collaboration for use in assisted reproduction [1][1] - These three core products are either in commercialization, new drug application (NDA) registration, or late-stage clinical trials in China, indicating a transition from pure research to commercialization for Baoji Pharmaceutical [1][1]
宝济药业-B首挂上市 早盘高开129.34% 旗下三大核心产品即将商业化